Benaglutide Benaglutide (HYBR-014) is the world's first human amino acid sequence GLP-1 drug independently developed by BENEMAE
Precise Concentrations : GHK-Cu 7.59 mg/mL, BPC-157 2.39 mg/mL, TB-500 1.99 mg/mL
SatoKSaigusaDKokubunTFujiokaAFengQSaitoRet al

doi: 10.34172/apb.43672 Original Article Zhipeng Zhang Data curation, Formal analysis, Resources, Software, Validation, Visualization, Writing original draft, Writing review & editing, 1, 2 Yanqin Ma Conceptualization, 2 Cheng Xie Resources, 2 Yan He Conceptualization, 2 Dong Wang Visualization, 2 Huaien Song Conceptualization, 2 Miao Yuan Data curation, Software, 3 Xiaomei Zhang Writing review & editing, 1, * Author information: 1 Laboratory of Pharmaceutical Engineering, School of Life Science and Health Engineering, Jiangnan University, Jiangnan University, Wuxi, China 2 Suzhou Hepa Thera Biopharmaceutical Co., Ltd., Shanghai, China 3 WuXi AppTec (Shanghai) Ltd., China Abstract Purpose: The objective of this study was to develop and produce a novel fusion protein that combines GLP-1 (glucagon-like peptide-1) and FGF21 (fibroblast growth factor 21), with the aim of achieving synergistic pharmacological effects through the targeting of dual pathways, followed by validation of these effects in a non-alcoholic steatohepatitis (NASH) model
